468 related articles for article (PubMed ID: 21392600)
1. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
[TBL] [Abstract][Full Text] [Related]
2. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE
J Am Coll Cardiol; 2013 Oct; 62(17):1580-4. PubMed ID: 23916935
[TBL] [Abstract][Full Text] [Related]
4. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
[TBL] [Abstract][Full Text] [Related]
5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
6. Effects of Extended-Release Niacin on Quartile Lp-PLA
Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
[TBL] [Abstract][Full Text] [Related]
7. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
[TBL] [Abstract][Full Text] [Related]
8. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
11. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
Teo KK; Goldstein LB; Chaitman BR; Grant S; Weintraub WS; Anderson DC; Sila CA; Cruz-Flores S; Padley RJ; Kostuk WJ; Boden WE;
Stroke; 2013 Oct; 44(10):2688-93. PubMed ID: 23881958
[TBL] [Abstract][Full Text] [Related]
12. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGHÂ trial.
Toth PP; Jones SR; Slee A; Fleg J; Marcovina SM; Lacy M; McBride R; Boden WE
J Clin Lipidol; 2018; 12(3):741-747.e11. PubMed ID: 29627296
[TBL] [Abstract][Full Text] [Related]
13. Extended-release niacin or ezetimibe and carotid intima-media thickness.
Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
[TBL] [Abstract][Full Text] [Related]
15. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
16. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
17. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group
Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
[TBL] [Abstract][Full Text] [Related]
18. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
Probstfield JL; Boden WE; Anderson T; Branch K; Kashyap M; Fleg JL; Desvigne-Nickens P; McBride R; McGovern M;
J Clin Lipidol; 2018; 12(6):1413-1419. PubMed ID: 30131256
[TBL] [Abstract][Full Text] [Related]
20. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ
J Am Coll Cardiol; 2010 Jun; 55(24):2721-6. PubMed ID: 20399059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
